Starting a highly effective treatment for relapsing-remitting multiple sclerosis (MS) soon after diagnosis is superior to starting an older, first-line agent and then escalating treatment, new research suggests. An examination of data from two national registries showed that, compared with treatment escalation, initiation of a highly effective agent was associated with a 29% reduction in […]
The investigational drug tolebrutinib effectively reduces brain lesions in patients with highly active relapsing-remitting multiple sclerosis (RRMS), new research suggests. After 12 weeks of treatment, MRI revealed the drug, a Bruton’s tyrosine kinase (BTK) inhibitor, was associated with a 93% reduction in new gadolinium-enhancing lesions and an 89% reduction in new and enlarging T2 lesions […]
Multiple sclerosis (MS) affects Whites, African Americans, and Hispanics differently, a new study finds, and there are big gaps in how they respond to disease-modifying therapies (DMTs). “Hispanics and African Americans develop a more severe disease course and accumulate more MS-related disability over time despite similar sociodemographic backgrounds and similar patterns of DMT use throughout their […]
